Literature DB >> 11323066

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.

D Moher1, K F Schulz, D G Altman.   

Abstract

To comprehend the results of a randomised controlled trial (RCT), readers must understand its design, conduct, analysis, and interpretation. That goal can be achieved only through total transparency from authors. Despite several decades of educational efforts, the reporting of RCTs needs improvement. Investigators and editors developed the original CONSORT (Consolidated Standards of Reporting Trials) statement to help authors improve reporting by use of a checklist and flow diagram. The revised CONSORT statement presented here incorporates new evidence and addresses some criticisms of the original statement. The checklist items pertain to the content of the Title, Abstract, Introduction, Methods, Results, and Discussion. The revised checklist includes 22 items selected because empirical evidence indicates that not reporting this information is associated with biased estimates of treatment effect, or because the information is essential to judge the reliability or relevance of the findings. We intended the flow diagram to depict the passage of participants through an RCT. The revised flow diagram depicts information from four stages of a trial (enrollment, intervention allocation, follow-up, and analysis). The diagram explicitly shows the number of participants, for each intervention group, included in the primary data analysis. Inclusion of these numbers allows the reader to judge whether the authors have done an intention-to-treat analysis. In sum, the CONSORT statement is intended to improve the reporting of an RCT, enabling readers to understand a trial's conduct and to assess the validity of its results.

Entities:  

Mesh:

Year:  2001        PMID: 11323066

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  879 in total

1.  Systematic reviews of evaluations of prognostic variables.

Authors:  D G Altman
Journal:  BMJ       Date:  2001-07-28

Review 2.  Improving safety reporting from randomised trials.

Authors:  John P A Ioannidis; Joseph Lau
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Better standards for better reporting of RCTs.

Authors:  P M Bossuyt
Journal:  BMJ       Date:  2001-06-02

4.  A medical early warning system.

Authors:  Jerome P Kassirer
Journal:  CMAJ       Date:  2002-04-30       Impact factor: 8.262

Review 5.  Systematic review of ceramic inlays.

Authors:  M Hayashi; N H F Wilson; C A Yeung; H V Worthington
Journal:  Clin Oral Investig       Date:  2002-12-21       Impact factor: 3.573

6.  Comment and perspective on Sewnath and colleagues' recent meta-analysis of the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice.

Authors:  Peter W T Pisters; Jeffrey E Lee; J Nicolas Vauthey; Douglas B Evans
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

7.  New BMJ policy on economic evaluations.

Authors:  Richard Smith
Journal:  BMJ       Date:  2002-11-16

8.  Standardized combined cryotherapy and compression using Cryo/Cuff after wrist arthroscopy.

Authors:  M Meyer-Marcotty; O Jungling; B Vaske; P M Vogt; Karsten Knobloch
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2010-10-07       Impact factor: 4.342

Review 9.  The Effects of Postprandial Exercise on Glucose Control in Individuals with Type 2 Diabetes: A Systematic Review.

Authors:  Andrew Borror; Gabriel Zieff; Claudio Battaglini; Lee Stoner
Journal:  Sports Med       Date:  2018-06       Impact factor: 11.136

10.  A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.

Authors:  Masao Omata; Haruhiko Yoshida; Joji Toyota; Eiichi Tomita; Shuhei Nishiguchi; Norio Hayashi; Shiro Iino; Isao Makino; Kiwamu Okita; Gotaro Toda; Kyuichi Tanikawa; Hiromitsu Kumada
Journal:  Gut       Date:  2007-06-15       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.